TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02295787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine for late-life depression and suicidal ideation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00614757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 20% 4ml
Description: N-acetylcysteine 20% 4ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 20% in 4 ml
Description: N-acetylcysteine 20% in 4 ml
Study: NCT02795468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial arterial cannulation
Description: Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial arterial cannulation
Description: Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
Study: NCT03693001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Exposure to Oxygen via Oro-Nasal Mask
Description: Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
Study: NCT04501016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral counseling
Description: Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobacco cessation pharmacotherapy
Description: Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
Study: NCT01922154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab
Description: The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycinC
Description: All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
Study: NCT02820181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel tracheostomy bi-ties
Description: The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Tracheostomy ties
Description: Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
Study: NCT00524680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally
Study: NCT01603394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
Study: NCT02617134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR-T cells
Study: NCT04148235

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT00384371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Botulinum Toxin A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04432454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene and abemaciclib (VERZENIO (R)).
Description: Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
Study: NCT00371995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B and Miltefosine
Description: Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)
Study: NCT04422977

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sars-Cov-2 serology
Description: Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
Study: NCT03908593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole (40mg qd) will be concomitant used with DAPT
Study: NCT03831269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nbUVB
Description: The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
Study: NCT01065363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized exercise program and dietary counseling
Description: Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
Study: NCT03519113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 80,000 IU
Description: recombinant human hepatitis B immunoglobulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102 100,000 IU
Description: recombinant human hepatitis B immunoglobulin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: I.V HBIG
Description: human anti-hepatitis B Immunoglobulin
Study: NCT02343380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calorimetric exam after a standard meal
Description: The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calorimetric exam after a standard meal
Description: The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
Study: NCT01259674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AboMeg-B-09
Description: Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup: 5ml to be taken 4 times a day during the entire study period
Study: NCT01733823

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
Study: NCT03908593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole (40mg qd) will be concomitant used with DAPT
Study: NCT04662983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-training
Description: A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
Study: NCT00115336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac
Description: Intravenous ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen, taken orally
Study: NCT01743976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5 mg once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo or sugar pill will be taken once daily for 6 weeks
Study: NCT02351336

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: 1. - Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. - corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. - CL measurement using 2D ultrasound ( in cm)
Study: NCT05037253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
Study: NCT01232400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached.
Study: NCT01966978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
Study: NCT03540290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modification of the implant supported prostheses in order to facilitate oral hygiene
Description: Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modification of the implant supported prostheses in order to facilitate oral hygiene
Description: Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
Study: NCT01733823

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
Study: NCT04116606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active JNJ-54175446
Description: JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing the same excipients
Study: NCT03208608

Intervention type: DIAGNOSTIC_TEST
Intervention: RBANS-H
Description: The RBANS-H is a diagnostic cognitive test battery
Study: NCT01553435

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: The study medicines shall be administered via tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medicines shall be administered via tube.
Study: NCT03749109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 1080 µg
Description: Vaginal ring containing Quinagolide 1080 µg for daily releases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02215785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
Study: NCT02081937

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR vector-transduced T cells
Study: NCT03559829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAPAEL Smart Glove
Description: The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
Study: NCT01536197

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Intervention: Gastric banding
Description: Laparoscopic adjustable gastric banding

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy surgery
Study: NCT04631588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Intradermal (ID) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Intradermal (ID) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal (ID) injection
Study: NCT03714542

Intervention type: OTHER
Group type: OTHER
Intervention: Pre- and postoperative MRI
Study: NCT01454388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breakfast
Study: NCT04477356

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SU
Description: Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DG
Description: Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
Study: NCT04567810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 IgY
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Study: NCT04286763

Intervention type: DIAGNOSTIC_TEST
Intervention: Biliary RMI and CT scan.
Description: For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biliary RMI and CT scan.
Description: For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients.
Study: NCT02914171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-derived Mononuclear Cells

Intervention type: DEVICE
Group type: OTHER
Intervention: Insertable cardiac monitor
Description: Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor
Description: Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
Study: NCT02188394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetic blockades with bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline injection
Study: NCT04211311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid high-intensity training
Description: FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
Study: NCT03471364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02294097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance protocol kidney allograft biopsy
Description: Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24